DK2316466T3 - Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering - Google Patents

Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering

Info

Publication number
DK2316466T3
DK2316466T3 DK09075579.4T DK09075579T DK2316466T3 DK 2316466 T3 DK2316466 T3 DK 2316466T3 DK 09075579 T DK09075579 T DK 09075579T DK 2316466 T3 DK2316466 T3 DK 2316466T3
Authority
DK
Denmark
Prior art keywords
treatment
positive bacteria
gram
diseases
preparations
Prior art date
Application number
DK09075579.4T
Other languages
English (en)
Inventor
Marie-Anne Nahori
Micheline Lagranderie
Gilles Marchal
Bernardo Boris Vargaftig
Jean Lefort
Felix Romain
Georges Hekimian
Philippe Peltre
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK2316466T3 publication Critical patent/DK2316466T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
DK09075579.4T 2001-12-11 2002-12-11 Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering DK2316466T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403195 2001-12-11
EP02804652A EP1461054B1 (en) 2001-12-11 2002-12-11 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Publications (1)

Publication Number Publication Date
DK2316466T3 true DK2316466T3 (da) 2013-11-18

Family

ID=8183013

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02804652.2T DK1461054T3 (da) 2001-12-11 2002-12-11 Gram-positive bakteriepræparater til behandling af sygdomme omfattende en immundysregulering
DK09075579.4T DK2316466T3 (da) 2001-12-11 2002-12-11 Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02804652.2T DK1461054T3 (da) 2001-12-11 2002-12-11 Gram-positive bakteriepræparater til behandling af sygdomme omfattende en immundysregulering

Country Status (17)

Country Link
US (3) US20060062807A1 (da)
EP (2) EP2316466B1 (da)
JP (2) JP4737586B2 (da)
KR (2) KR101124363B1 (da)
CN (1) CN1602199B (da)
AT (1) ATE466585T1 (da)
AU (1) AU2002356387C1 (da)
BR (1) BR0214902A (da)
CA (1) CA2469334C (da)
CY (1) CY1110727T1 (da)
DE (1) DE60236318D1 (da)
DK (2) DK1461054T3 (da)
ES (1) ES2345188T3 (da)
NZ (2) NZ555055A (da)
PT (1) PT1461054E (da)
SI (1) SI1461054T1 (da)
WO (1) WO2003049752A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469334C (en) 2001-12-11 2012-05-08 Institut Pasteur Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
WO2004022093A1 (en) * 2002-09-06 2004-03-18 University College London Whole bacterial cells as immune modulator
WO2005049056A2 (en) * 2003-11-14 2005-06-02 Ucl Biomedica Plc Immune modulator comprising whole cell rhodococcus, gordonia, nocardia, dietzia, tsukamurella or nocardioides bacteria
WO2005080414A1 (en) 2004-02-19 2005-09-01 Ramot At Tel-Aviv University Ltd Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
WO2008049231A1 (en) * 2006-10-27 2008-05-02 Harold David Gunn Tissue targeted antigenic activation of the immune response to treat cancers
NZ586338A (en) * 2004-06-07 2012-02-24 Qu Biolog Inc Bacterial compositions for the treatment of cancer
WO2006001011A1 (en) 2004-06-24 2006-01-05 Yissum Research Development Company Use of mycobacterial mannosylated lipoglycans peptide mimotopes for treating inflammation
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
EP2087898A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis
CA2629057A1 (en) * 2008-04-14 2009-10-14 Institut Pasteur Control of diseases associated with decrease of t-regulatory cells with a preparation of extended freeze-dried killed bacteria
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
EP3137108A4 (en) 2014-05-02 2017-09-27 Qu Biologics Inc Anti-microbial immunomodulation
AU2017222692A1 (en) * 2016-02-25 2018-09-27 Thomas Julius Borody Compositions and methods of treatment of chronic infectious diseases
CN113226342A (zh) * 2018-10-17 2021-08-06 西巴克股份有限公司 治疗和预防肺部状况的活的生物治疗剂
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens
JP7441534B2 (ja) * 2019-01-09 2024-03-01 エムディー ヘルスケア インコーポレイテッド ロドコッカス属細菌由来ナノ小胞およびその用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594471A (en) * 1946-10-11 1952-04-29 Comb Eng Superheater Inc Heat exchange apparatus
GB764718A (en) * 1954-08-10 1957-01-02 Glaxo Lab Ltd Improvements in or relating to freeze-drying processes
GB1027979A (en) * 1963-07-12 1966-05-04 Ciba Ltd Process for obtaining bcg-cultures
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
JPS57186495A (en) 1981-05-14 1982-11-16 Ube Ind Ltd Preparation of l-alpha-methylphenylalanine
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IN164864B (da) 1985-05-13 1989-06-24 Commw Scient Ind Res Org
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPS63126830A (ja) * 1986-11-17 1988-05-30 Isao Moriya 動植物の体内に抗体を生成する方法
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
CA2469334C (en) 2001-12-11 2012-05-08 Institut Pasteur Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Also Published As

Publication number Publication date
US20070190076A1 (en) 2007-08-16
US20060062807A1 (en) 2006-03-23
JP2011121977A (ja) 2011-06-23
AU2002356387C1 (en) 2008-03-06
WO2003049752A3 (en) 2003-11-20
US7871627B2 (en) 2011-01-18
EP1461054A2 (en) 2004-09-29
US20100272756A1 (en) 2010-10-28
CN1602199A (zh) 2005-03-30
AU2002356387A1 (en) 2003-06-23
EP1461054B1 (en) 2010-05-05
NZ533422A (en) 2008-03-28
EP2316466A2 (en) 2011-05-04
ES2345188T3 (es) 2010-09-17
CA2469334C (en) 2012-05-08
PT1461054E (pt) 2010-08-09
KR20040080434A (ko) 2004-09-18
EP2316466A3 (en) 2012-04-11
DE60236318D1 (de) 2010-06-17
EP2316466B1 (en) 2013-08-21
HK1067073A1 (en) 2005-04-01
JP2005516915A (ja) 2005-06-09
CN1602199B (zh) 2012-04-04
ATE466585T1 (de) 2010-05-15
JP5417354B2 (ja) 2014-02-12
KR101124363B1 (ko) 2012-03-21
CA2469334A1 (en) 2003-06-19
CY1110727T1 (el) 2015-06-10
NZ555055A (en) 2010-06-25
DK1461054T3 (da) 2010-08-16
JP4737586B2 (ja) 2011-08-03
KR101048798B1 (ko) 2011-07-15
AU2002356387B2 (en) 2007-09-13
WO2003049752A2 (en) 2003-06-19
BR0214902A (pt) 2004-11-30
SI1461054T1 (sl) 2010-09-30
US8404250B2 (en) 2013-03-26
KR20110028558A (ko) 2011-03-18

Similar Documents

Publication Publication Date Title
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
NO20034056D0 (no) Proliferative sykdommer
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
DE60233801D1 (de) Verfahren zur behandlung von gelenkentzündung, schmerzen und mobilitätsverlust
EP1262177A3 (en) Medical use of thyromimetic compounds to treat hair loss and compositions
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
WO2002078742A3 (en) Methods and compositions for treatment of immune dysfunction disorders
DK1037650T3 (da) Præparater til behandling af Staphylococcus aureus-infektioner
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
WO2006004588A3 (en) Immunodynamic complexes and methods for using and preparing such complexes
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2003013440A3 (en) Treatment and prevention of heat shock protein-associated diseases and conditions
BR0111785A (pt) Composições e métodos para tratamento de candidìase
ATE458004T1 (de) Osteoprotegerin in milch
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
DE60231994D1 (de) Mittel zur behandlung oder prävention allergischerg
ATE339899T1 (de) Aromakonservierendes mittel
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
WO2000041526A3 (en) Use of s-triazines for treating apicomplexan parasitic infections